385 related articles for article (PubMed ID: 34941867)
1. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
[TBL] [Abstract][Full Text] [Related]
2. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
Wilson MR; Reske JJ; Holladay J; Wilber GE; Rhodes M; Koeman J; Adams M; Johnson B; Su RW; Joshi NR; Patterson AL; Shen H; Leach RE; Teixeira JM; Fazleabas AT; Chandler RL
Nat Commun; 2019 Aug; 10(1):3554. PubMed ID: 31391455
[TBL] [Abstract][Full Text] [Related]
3. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
[TBL] [Abstract][Full Text] [Related]
5. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
Russo M; Newell JM; Budurlean L; Houser KR; Sheldon K; Kesterson J; Phaeton R; Hossler C; Rosenberg J; DeGraff D; Shuman L; Broach JR; Warrick JI
Cancer; 2020 Jun; 126(12):2775-2783. PubMed ID: 32187665
[TBL] [Abstract][Full Text] [Related]
6. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.
Megino-Luque C; Sisó P; Mota-Martorell N; Navaridas R; de la Rosa I; Urdanibia I; Albertí-Valls M; Santacana M; Pinyol M; Bonifaci N; Macià A; Llobet-Navas D; Gatius S; Matias-Guiu X; Eritja N
Mol Oncol; 2022 Jun; 16(11):2235-2259. PubMed ID: 35167193
[TBL] [Abstract][Full Text] [Related]
7. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
[TBL] [Abstract][Full Text] [Related]
8. Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.
Loe AKH; Francis R; Seo J; Du L; Wang Y; Kim JE; Hakim SW; Kim JE; He HH; Guo H; Kim TH
J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33822841
[TBL] [Abstract][Full Text] [Related]
9. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
10. Two Distinct Tumorigenic Processes in Endometrial Endometrioid Adenocarcinoma.
Sugiyama Y; Gotoh O; Fukui N; Tanaka N; Hasumi K; Takazawa Y; Noda T; Mori S
Am J Pathol; 2020 Jan; 190(1):234-251. PubMed ID: 31733184
[TBL] [Abstract][Full Text] [Related]
11. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
[TBL] [Abstract][Full Text] [Related]
12. S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
Yuan W; Goldstein LD; Durinck S; Chen YJ; Nguyen TT; Kljavin NM; Sokol ES; Stawiski EW; Haley B; Ziai J; Modrusan Z; Seshagiri S
Breast Cancer Res; 2019 Dec; 21(1):152. PubMed ID: 31881983
[TBL] [Abstract][Full Text] [Related]
13. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis.
Asaka S; Liu Y; Yu ZC; Rahmanto YS; Ono M; Asaka R; Miyamoto T; Yen TT; Ayhan A; Wang TL; Shih IM
Mod Pathol; 2023 Feb; 36(2):100045. PubMed ID: 36853791
[TBL] [Abstract][Full Text] [Related]
14. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA.
Watkins JC; Howitt BE; Horowitz NS; Ritterhouse LL; Dong F; MacConaill LE; Garcia E; Lindeman NI; Lee LJ; Berkowitz RS; Nucci MR; Crum CP
Mod Pathol; 2017 Mar; 30(3):448-458. PubMed ID: 27834349
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I
Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma.
Yang T; Qiu H; Bao W; Li B; Lu C; Du G; Luo X; Wang L; Wan X
PLoS One; 2013; 8(6):e67458. PubMed ID: 23840707
[TBL] [Abstract][Full Text] [Related]
17. Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma.
Susini T; Massi D; Paglierani M; Masciullo V; Scambia G; Giordano A; Amunni G; Massi G; Taddei GL
Hum Pathol; 2001 Apr; 32(4):360-7. PubMed ID: 11331952
[TBL] [Abstract][Full Text] [Related]
18. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
19. Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium.
Suda K; Nakaoka H; Yoshihara K; Ishiguro T; Tamura R; Mori Y; Yamawaki K; Adachi S; Takahashi T; Kase H; Tanaka K; Yamamoto T; Motoyama T; Inoue I; Enomoto T
Cell Rep; 2018 Aug; 24(7):1777-1789. PubMed ID: 30110635
[TBL] [Abstract][Full Text] [Related]
20. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
